The Utility of NGS Analysis in Homologous Recombination Deficiency Tracking
Several tumor types have been efficiently treated with PARP inhibitors (PARPis), which are now approved for the treatment of ovarian, breast, prostate, and pancreatic cancers. The <i>BRCA1/2</i> genes and mutations in many additional genes involved in the HR pathway may be responsible fo...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-09-01
|
Series: | Diagnostics |
Subjects: | |
Online Access: | https://www.mdpi.com/2075-4418/13/18/2962 |